​

enGene (ENGN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ENGN Stock Forecast

enGene (ENGN) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $4.00 and a low of $2.00. This represents a 70.45% increase from the last price of $1.76.

- $4 $8 $12 $16 $20 High: $4 Avg: $3 Low: $2 Last Closed Price: $1.76

ENGN Stock Rating

enGene stock's rating consensus is Hold, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (33.33%), 5 Hold (55.56%), 1 Sell (11.11%), and 0 Strong Sell (0.00%).

Hold
Total 9 0 1 5 3 Strong Sell Sell Hold Buy Strong Buy

ENGN Price Target Upside V Benchmarks

TypeNameUpside
StockenGene70.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-712
Avg Price Target-$3.00$12.00
Last Closing Price$1.76$1.76$1.76
Upside/Downside-70.45%581.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261261-10
Jun, 26128--11
May, 26271--10
Apr, 26271--10
Mar, 26361--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 18, 2026Judah FrommerMorgan Stanley$3.00$1.7472.41%70.45%
Jun 16, 2026Andres MaldonadoH.C. Wainwright$4.00$1.77125.99%127.27%
May 14, 2026UBS$2.00$1.6322.70%13.64%
May 08, 2026Market PerformLeerink Partners$2.00$1.7216.28%13.64%
May 08, 2026Raymond James$4.00$1.72132.56%127.27%
May 08, 2026Allison BratzelPiper Sandler$4.00$1.72132.56%127.27%
May 08, 2026Wells Fargo$2.00$1.7216.28%13.64%
Mar 09, 2026Sean McCutcheonRaymond James$27.00$7.79246.60%1434.09%
Jan 30, 2026Jefferies$28.00$10.27172.64%1490.91%
Dec 03, 2025Andres MaldonadoH.C. Wainwright$25.00$7.86218.07%1320.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2026Morgan StanleyUnderweightdowngrade
Jun 16, 2026H.C. WainwrightBuyBuyhold
May 08, 2026OppenheimerOutperformPerformdowngrade
May 08, 2026Raymond JamesStrong BuyOutperformdowngrade
May 08, 2026Piper SandlerNeutraldowngrade
May 08, 2026CitigroupMarket OutperformMarket Performdowngrade
May 07, 2026GuggenheimBuyNeutraldowngrade
Mar 10, 2026GuggenheimBuyBuyhold
Mar 09, 2026Raymond JamesStrong BuyStrong Buyhold
Jan 30, 2026JefferiesBuyinitialise

Financial Forecast

EPS Forecast

Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported$-1.46$-2.29----
Avg Forecast$-1.46$-1.60$-1.91$-1.82$-0.75$0.06
High Forecast$-1.36$-1.32$-1.63$-1.82$-0.75$0.06
Low Forecast$-1.57$-1.88$-2.33$-1.82$-0.75$0.06
Surprise %-43.13%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported------
Avg Forecast--$4.78M$30.75M$118.72M$260.97M
High Forecast--$4.78M$30.75M$118.72M$260.97M
Low Forecast--$4.78M$30.75M$118.72M$260.97M
Surprise %------

Net Income Forecast

$-900M $-690M $-480M $-270M $-60M $150M Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported$-55.14M$117.30M----
Avg Forecast$-551.62M$-604.49M$-722.29M$-688.59M$-284.12M$23.61M
High Forecast$-515.33M$-500.53M$-616.30M$-688.59M$-284.12M$23.61M
Low Forecast$-591.54M$-708.45M$-879.30M$-688.59M$-284.12M$23.61M
Surprise %-90.00%-119.41%----

ENGN Forecast FAQ

Is enGene stock a buy?

enGene stock has a consensus rating of Hold, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that enGene is a neutral investment for most analysts.

What is enGene's price target?

enGene's price target, set by 9 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $2 at the low end to $4 at the high end, suggesting a potential 70.45% change from the previous closing price of $1.76.

How does enGene stock forecast compare to its benchmarks?

enGene's stock forecast shows a 70.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for enGene over the past three months?

  • July 2026: 10.00% Strong Buy, 20.00% Buy, 60.00% Hold, 10.00% Sell, 0% Strong Sell.
  • June 2026: 9.09% Strong Buy, 18.18% Buy, 72.73% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is enGene’s EPS forecast?

enGene's average annual EPS forecast for its fiscal year ending in October 2026 is $-1.91, marking a -16.59% decrease from the reported $-2.29 in 2025. Estimates for the following years are $-1.82 in 2027, $-0.75 in 2028, and $0.06 in 2029.

What is enGene’s revenue forecast?

enGene's average annual revenue forecast for its fiscal year ending in October 2026 is $4.78M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $30.75M, followed by $118.72M for 2028, and $260.97M for 2029.

What is enGene’s net income forecast?

enGene's net income forecast for the fiscal year ending in October 2026 stands at $-722M, representing a -715.75% decrease from the reported $117.3M in 2025. Projections indicate $-689M in 2027, $-284M in 2028, and $23.61M in 2029.